» Articles » PMID: 35158869

Metastatic Breast Cancer Recurrence After Bone Fractures

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Feb 15
PMID 35158869
Authors
Affiliations
Soon will be listed here.
Abstract

Experimental studies suggest that bone fractures result in the release of cytokines and cells that might promote metastasis. Obtaining observational data on bone fractures after breast cancer diagnoses related to distant breast cancer recurrence could help to provide first epidemiological evidence for a metastasis-promoting effect of bone fractures. We used data from the largest German statutory health insurance fund (Techniker Krankenkasse, Hamburg, Germany) in a population-based cohort study of breast cancer patients with ICD-10 C50 codes documented between January 2015 and November 2019. The risk of metastasis overall, regional, distant non-bone or bone metastasis related to a fracture was modeled by an adjusted discrete time-to-event analysis with time-dependent exposure. Of 154,000 breast cancer patients, 84,300 fulfilled the inclusion criteria and had a follow-up time of more than half a year. During follow-up, fractures were diagnosed in 13,579 (16.1%) patients. Metastases occurred in 7047 (8.4%) patients; thereof 1544 had affected regional lymph nodes only and 5503 distant metastases. Fractures demonstrated a statistically significant association with subsequent metastasis overall (adjusted HR 1.12, 95% CI 1.04, 1.20). The highest risk for metastasis was observed in patients with subsequent bone metastasis (adjusted HR 1.18, 95% CI 1.05, 1.34), followed by distant non-bone metastasis (adjusted HR 1.16, 95% CI 1.07, 1.26) and lymph node metastasis (adjusted HR 1.08, 95% CI 0.97, 1.21).

Citing Articles

Bone Metastasis Initiation Is Coupled with Bone Remodeling through Osteogenic Differentiation of NG2+ Cells.

Zhang W, Xu Z, Hao X, He T, Li J, Shen Y Cancer Discov. 2022; 13(2):474-495.

PMID: 36287038 PMC: 9905315. DOI: 10.1158/2159-8290.CD-22-0220.

References
1.
Cronin-Fenton D, Kjaersgaard A, Norgaard M, Amelio J, Liede A, Hernandez R . Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark. Breast Cancer Res Treat. 2017; 167(2):517-528. DOI: 10.1007/s10549-017-4510-3. View

2.
Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich C . Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 2000; 342(8):525-33. DOI: 10.1056/NEJM200002243420801. View

3.
Bahney C, Zondervan R, Allison P, Theologis A, Ashley J, Ahn J . Cellular biology of fracture healing. J Orthop Res. 2018; 37(1):35-50. PMC: 6542569. DOI: 10.1002/jor.24170. View

4.
Riethdorf S, Muller V, Loibl S, Nekljudova V, Weber K, Huober J . Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. Clin Cancer Res. 2017; 23(18):5384-5393. DOI: 10.1158/1078-0432.CCR-17-0255. View

5.
Braun S, Vogl F, Naume B, Janni W, Osborne M, Coombes R . A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005; 353(8):793-802. DOI: 10.1056/NEJMoa050434. View